Brief: EyeGate Pharma Appoints Eric Daniels As Chief Development Officer And Closes Acquisition Of Bayon Therapeutics
26/10/2021 12:53
Oct 26 (Reuters) - EyeGate Pharmaceuticals Inc EYEG.O :
* EYEGATE PHARMACEUTICALS APPOINTS ERIC J. DANIELS, MD, MBA,
AS
CHIEF DEVELOPMENT OFFICER AND CLOSES ACQUISITION OF BAYON
THERAPEUTICS, INC.
Source text for Eikon: ID:nGNX7Qs3S1
Further company coverage: EYEG.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Kiora Pharmaceuticals
See all newsKiora Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Kiora Pharmaceuticals, Inc. expected to post a loss of 62 cents a share - Earnings Preview
Brief: Kiora Pharmaceuticals Inc - Enters Securities Purchase Agreement On April 3, 2026 - SEC Filing
Kiora Pharmaceuticals posts 2025 net loss as expenses rise
Brief: Kiora Pharmaceuticals Files For Mixed Shelf Offering Of Up To $100 Million- SEC Filing